A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Amgen2,423 enrolled

Overview

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,423

Conditions

Anemia

Interventions

AranespDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with nonmyeloid malignancy(ies) * Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy Exclusion Criteria: * Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS) * Unstable cardiac disease or anemia due to other causes

Outcomes

Primary Outcomes

Patient reported outcomes

Secondary Outcomes

Changes in hemoglobin endpoints and RBC transfusion requirements

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.